In a filing, Rani Therapeutics Holdings Inc revealed its 10% Owner South Cone Investments Limited unloaded Company’s shares for reported $10.14 million on Oct 15 ’24. In the deal valued at $2.65 per share,3,829,360 shares were sold. As a result of this transaction, South Cone Investments Limited now holds 8,302,194 shares worth roughly $17.02 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Quiroga Cortes Isidoro Alfonso sold 5,265,165 shares, generating $10,582,982 in total proceeds. Upon selling the shares at $2.01, the 10% Owner now owns 8,400 shares.
Before that, South Cone Investments Limited bought 5,265,165 shares. Rani Therapeutics Holdings Inc shares valued at $10,582,982 were divested by the 10% Owner at a price of $2.01 per share. As a result of the transaction, South Cone Investments Limited now holds 12,131,554 shares, worth roughly $24.87 million.
Oppenheimer initiated its Rani Therapeutics Holdings Inc [RANI] rating to an Outperform in a research note published on August 02, 2024; the price target was $17. A number of analysts have revised their coverage, including Maxim Group’s analysts, who began to cover the stock in mid June with a ‘”a Buy”‘ rating. Rodman & Renshaw began covering RANI with “Buy” recommendation on June 13, 2024.
Price Performance Review of RANI
On Monday, Rani Therapeutics Holdings Inc [NASDAQ:RANI] saw its stock fall -9.69% to $2.05. Over the last five days, the stock has lost -21.76%. Rani Therapeutics Holdings Inc shares have fallen nearly -38.25% since the year began. Nevertheless, the stocks have risen 3.54% over the past one year. While a 52-week high of $8.75 was reached on 04/17/24, a 52-week low of $1.90 was recorded on 11/18/24. SMA at 50 days reached $2.36, while 200 days put it at $3.63.
Levels Of Support And Resistance For RANI Stock
The 24-hour chart illustrates a support level at 1.94, which if violated will result in even more drops to 1.82. On the upside, there is a resistance level at 2.23. A further resistance level may holdings at 2.40. The Relative Strength Index (RSI) on the 14-day chart is 39.08, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.17, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 92.54%. Stochastics %K at 17.54% indicates the stock is a buying.
How much short interest is there in Rani Therapeutics Holdings Inc?
A steep rise in short interest was recorded in Rani Therapeutics Holdings Inc stocks on 2024-10-31, growing by 0.7 million shares to a total of 1.49 million shares. Yahoo Finance data shows the prior-month short interest on 2024-09-30 was 0.79 million shares. There was a rise of 47.12%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on October 11, 2022 when UBS began covering the stock and recommended ‘”a Buy”‘ rating along with a $15 price target.
